More on the Survival and Ventricular Enlargement Trial

More on the Survival and Ventricular Enlargement Trial

To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue) 1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1993-10, Vol.329 (16), p.1204-1206
Hauptverfasser: Ganley, Charles J, Hung, H.M. James, Temple, Robert, Pfeffer, Marc A, Moye, Lemuel A, Rutherford, John, Braunwald, Eugene
Format: Artikel
Sprache:eng
Schlagworte:
Captopril - therapeutic use
Electrocardiography
Humans
Hypertrophy, Left Ventricular - drug therapy
Hypertrophy, Left Ventricular - physiopathology
Myocardial Infarction - physiopathology
Recurrence
Ventricular Function, Left
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue) 1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199310143291616